News | December 19, 2006

Payor Backs Door to Balloon Initiative

UnitedHealthcare has announced its support for the “Door to Balloon (D2B): An Alliance for Quality” campaign recently initiated by the ACC and supported by 22 partnering organizations including the American Heart Association (AHA). The campaign aims to improve door to balloon time, which is the interval between a patient’s arrival at the hospital and the opening of a blocked artery with an angioplasty balloon. Patients who receive prompt treatment are more likely to survive a common type of heart attack.

The consumer health benefits company had incorporated D2B as one of the quality measurements in its UnitedHealth Premium designation program for cardiac facilities nationwide. The tangible outcome of its support will be demonstrated by increasing the weight of measurement assigned to the D2B performance standard — a facility that lowers D2B time will receive a higher quality score.

Under the UnitedHealth Premium program, facilities seeking designation status must submit clinical outcomes data, resulting in increased access to unparalleled datasets on performance against cardiac care criteria established by recognized experts that cardiac facilities, physicians and patients can use to make informed choices.

“We believe that providing hospitals, physicians and health care professionals with evidence-based information they can use to analyze clinical performance is one of the most important ways to improve clinical quality,” said Reed Tuckson, M.D., executive vice president and chief of medical affairs for UnitedHealth Group in a press release. “We commend the American College of Cardiology and the American Heart Association for taking a leadership role to improve timeliness of treatment, representing an important opportunity to improve the quality of patient care. This should come as welcome news for the millions of Americans – and their families – who suffer from heart disease and expect to receive the best care and information.”


Related Content

News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Balloon Catheter

July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...

Home July 15, 2019
Home
Subscribe Now